By order of the Board of Directors /s/ Nevan Charles Elam Nevan Charles Elam Chief Executive Officer and Acting Chairman of the Board Redwood City, California | |||||
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 6 | | | |
| ||||||||
| | | | 17 | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| ||||||||
| | | | |||||
| |
Name | | | Age | | | Position | | | Date Appointed | |
Nevan Charles Elam | | | | | Chief Executive Officer, | | | January 31, 2013 | | |
Gil Labrucherie | | | 51 | | | Director | | | November 20, 2019 | |
Nerissa Kreher | | | 50 | | | Director | | | March 2, 2021 | |
Philippe Fauchet | | | | | Director | | | September 10, 2020 | | |
Wladimir Hogenhuis | | | | | Director | | | March 2, 2021 | | |
| | | | Director | | | |
Total Number of Directors | | | 6 | | |||||||||
| | | Male | | | Female | | ||||||
Part I: Gender Identity | | | | | | | | | | | | | |
Directors | | | | | 5 | | | | | | 1 | | |
Part II: Demographic Background | | | | | | | | | | | | | |
White | | | | | 3 | | | | | | 1 | | |
African American or Black | | | | | 1 | | | | | | — | | |
Asian | | | | | 1 | | | | | | — | | |
Did Not Disclose Demographic Background | | | | | — | | | | | | — | | |
Directors who are Military Veterans | | | | | 1 | | | | | | — | | |
| | | |||||||||||||||||
| | Audit | | | Compensation | | | Nominating and Governance | | ||||||||||
Committee Members as of June 30, 2022: | | | | | | | | | | | |||||||||
Gil Labrucherie(1) | | | X | | | X | | | X | | |||||||||
| | | | | X | | | X | | ||||||||||
| | X | | | X | | | X | | ||||||||||
| | X | |||||||||||||||||
| | X | | | X | |
Name | | | Fees Earned or Paid in Cash ($) | | | Option Awards ($) | | | Total ($) | | |||||||||
Gil Labrucherie | | | | | 57,000 (1) | | | | | | 211,168(7) | | | | | | 268,168 | | |
Nerissa Kreher | | | | | 47,000(2) | | | | | | 211,168(7) | | | | | | 258,168 | | |
Phillippe Fauchet | | | | | 57,000(3) | | | | | | 211,168(7) | | | | | | 268,168 | | |
Wladimir Hogenhuis | | | | | 54,000(4) | | | | | | 211,168(7) | | | | | | 265,168 | | |
Young-Jin Kim | | | | | —(5) | | | | | | 105,584(8) | | | | | | 105,584 | | |
| | | Shares Underlying Options Outstanding | | |||||||||
| | | Vested | | | Unvested | | ||||||
Gil Labrucherie | | | | | 8,554 | | | | | | 84,446 | | |
Philippe Fauchet | | | | | 5,110 | | | | | | 84,890 | | |
Wladimir Hogenhuis | | | | | 3,333 | | | | | | 86,667 | | |
Nerissa Kreher | | | | | 3,333 | | | | | | 86,667 | | |
Young-Jin Kim | | | | | — | | | | | | 40,000 | | |
Name of Beneficial Owner | | | Position with Company | | | Beneficial Ownership | | | Percent of Class | | ||||||
Stockholders in excess of 5% | | | | | | | | | | | | | | | | |
Entities associated with Federated Hermes, Inc. | | | Stockholder | | | | | 7,549,032(1) | | | | | | 19.9% | | |
Handok Inc. | | | Stockholder | | | | | | | | | | | | ||
| | Stockholder | | | | | | | | | | | | |||
| | Stockholder | | | | | ||||||||||
| | | | | ||||||||||||
| | |||||||||||||||
Directors and Executive Officers: | | | | | | | | | | | | | | | | |
| | Chief Executive Officer and Acting Chairman of the Board | | | | | | | | | | |||||
| | |||||||||||||||
Gil Labrucherie | | | Director | | | | | | | | | | * | | | |
Philippe Fauchet | | | Director | | | | | | | | | | * | | | |
| | | | | | |||||||||||
| | | | | * | | | |||||||||
Wladimir Hogenhuis | | | Director | | | | | 66,025(9) | | | | | | * | | |
Young-Jin Kim | | | Director | | | | | 6,034,897(10) | | | | | | 16.4% | | |
Brian Roberts | | | Chief Medical Officer | | | | | 118,802(11) | | | | | | * | | |
Directors and executive officers as a group (7 people) | | | | | | | | | | | | | | |
| | | Plan Termination Date | | | Shares to be Issued Upon Exercise of Outstanding Options: | | | Securities Available For Future Issuance | | | ||||||||||||||
| Number of Shares | | | Weighted Average Exercise Price | | | |||||||||||||||||||
Equity compensation plans approved by security holders: | | | | | | | | | | | | | | | | | | | | | | | | ||
2015 Non-Qualified Stock Option Plan | | | February 23, 2020 | | | | | 36 | | | | | $ | 50.73 | | | | | | — | | | | ||
2016 Non-Qualified Stock Option Plan | | | October 31, 2021 | | | | | 256 | | | | | | 22.77 | | | | | | — | | | | ||
2021 Equity Incentive Plan | | | March 31, 2031 | | | | | 8,014 | | | | | | 4.24 | | | | | | 2,686 | | | | ||
Equity compensation plans not approved by security holders: | | | | | | | | | | | | | | | | | | | | | | | | ||
2019 Non Qualified Stock Option Plan | | | July 31, 2029 | | | | | 200 | | | | | | 14.50 | | | | | | — | | | | ||
Total | | | | | | | | 8,506 | | | | | | 5.24 | | | | | | 2,686 | | | | | |
| | 2020 | | 2019 | | | 2022 | | 2021 | | ||||||||||||||||||||||||||||||||||||||||
| | Amount | | Percent | | Amount | | Percent | | | Amount | | Percent | | Amount | | Percent | | ||||||||||||||||||||||||||||||||
Audit fees | | | $ | 142,000 | | | | | 92% | | | | $ | 142,035 | | | | | 100% | | | | | $ | 259,000 | | | | | 85% | | | | $ | 175,500 | | | | | 82% | | | ||||||||
Audit-related fees | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||
Tax fees | | | | 12,000 | | | | | 8% | | | | | — | | | | | — | | | | | | 47,225 | | | | | 15% | | | | | 38,100 | | | | | 18% | | | ||||||||
All other fees | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||
Total | | | $ | 154,000 | | | | | 100% | | | | $ | 142,035 | | | | | 100% | | | | | $ | 306,225 | | | | | 100% | | | | $ | 213,600 | | | | | 100% | | |
| | | | | | As of April 15, 2021 | | | As of June 30, 2020 | | ||||||||||||||||||||||||||||||
| | | Plan Termination Date | | | Shares to be Issued Upon Exercise of Outstanding Options: | | | Securities Available For Future Issuance | | | Shares to be Issued Upon Exercise of Outstanding Options: | | | Securities Available For Future Issuance | | ||||||||||||||||||||||||
| | | Number of Shares | | | Weighted Average Exercise Price | | | Number of Shares | | | Weighted Average Exercise Price | | |||||||||||||||||||||||||||
Equity compensation plans approved by security holders: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
2014 Stock and Incentive Plan | | | March 21, 2019 | | | | | 3,099 | | | | | $ | 120.43 | | | | | | — | | | | | | 43,708 | | | | | $ | 153.47 | | | | | | — | | |
2015 Non-Qualified Stock Option Plan | | | February 23, 2020 | | | | | 87,700 | | | | | | 59.85 | | | | | | — | | | | | | 95,100 | | | | | | 55.19 | | | | | | — | | |
2016 Non-Qualified Stock Option Plan | | | October 31, 2021 | | | | | 483,550 | | | | | | 30.74 | | | | | | 76,450 | | | | | | 524,300 | | | | | | 29.63 | | | | | | 35,700 | | |
Equity compensation plans not approved by security holders: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
2019 Non Qualified Stock Option Plan | | | July 31, 2029 | | | | | 300,000 | | | | | | 14.50 | | | | | | — | | | | | | 300,000 | | | | | | 14.50 | | | | | | — | | |
Total | | | | | | | | 874,349 | | | | | | 28.41 | | | | | | 76,450 | | | | | | 963,108 | | | | | | 33.06 | | | | | | 35,700 | | |
Name | | | Age | | | Position | | | Date Appointed | |
Nevan Charles Elam | | | | | Chief Executive Officer, Principal Financial Officer and | | | January 31, 2013 | | |
| | 48 | | | ||||||
| | |||||||||
|
Name and Position | | | Fiscal Year | | | Salary | | | Bonus | | | Stock Option Awards | | | All Other Compensation | | | Total | | ||||||||||||||||||
Nevan Charles Elam, | | | | | 2020 | | | | | $ | 490,000(1) | | | | | $ | 97,020(4) | | | | | $ | 2,688,000(6) | | | | | $ | 23,683(7) | | | | | $ | 3,298,703 | | |
Chief Executive Officer | | | | | 2019 | | | | | | 453,333(1) | | | | | | 258,750(5) | | | | | | — | | | | | | 20,163(7) | | | | | | 732,246 | | |
Sankaram Mantripragada, | | | | | 2020 | | | | | $ | 350,000(2) | | | | | $ | 57,750(4) | | | | | $ | 627,000(6) | | | | | $ | 31,883(8) | | | | | $ | 1,066,633 | | |
Scientist Emeritus | | | | | 2019 | | | | | | 350,000(2) | | | | | | 181,125(5) | | | | | | — | | | | | | 31,269(8) | | | | | | 562,394 | | |
Keith Vendola, | | | | | 2020 | | | | | $ | 365,000(3) | | | | | $ | 36,135(4) | | | | | $ | 538,000(6) | | | | | $ | 13,581(9) | | | | | $ | 952,716 | | |
Former Chief Financial Officer | | | | | 2019 | | | | | | 330,000(3) | | | | | | 8,044(5) | | | | | | 395,723(6) | | | | | | 1,605 | | | | | | 735,372 | | |
Name and Position | | | Fiscal Year | | | Salary | | | Bonus | | | Stock Option Awards | | | All Other Compensation | | | Total | | |||||||||||||||
Nevan Charles Elam | | | 2022 | | | | $ | 515,000(1) | | | | | $ | 378,750(3) | | | | | $ | 6,862,960(5) | | | | | $ | 24,590(6) | | | | | $ | 7,781,300 | | |
Chief Executive Officer | | | 2021 | | | | $ | 495,682(1) | | | | | $ | 490,980(4) | | | | | $ | 3,888,117(5) | | | | | $ | 21,953(6) | | | | | $ | 4,896,732 | | |
Brian Roberts, M.D. | | | 2022 | | | | $ | 401,500(2) | | | | | $ | 121,875(3) | | | | | $ | 1,847,720(5) | | | | | $ | 52,053(7) | | | | | $ | 2,423,148 | | |
Chief Medical Officer | | | 2021 | | | | $ | 371,364(2) | | | | | $ | 171,300(4) | | | | | $ | 775,203(5) | | | | | $ | 36,074(8) | | | | | $ | 1,353,941 | | |
Name | | | Grant Date | | | Vesting Type | | | Number of Securities Underlying | | | Option Exercise Price | | | Option Expiration Date | | |||||||||||||||||||||
| Unexercised Options | | |||||||||||||||||||||||||||||||||||
| Exercisable | | | Unexercisable | | ||||||||||||||||||||||||||||||||
Nevan Charles Elam(1): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 3/26/14 | | | | | | Time | | | | | | 27,000 | | | | | | — | | | | | $ | 156.00 | | | | | | 3/26/21 | | |
| | | | | 2/23/15 | | | | | | Time | | | | | | 34,800 | | | | | | — | | | | | | 103.00 | | | | | | 2/23/25 | | |
| | | | | 12/28/16 | | | | | | Time | | | | | | 61,250 | | | | | | 8,750 | | | | | | 60.00 | | | | | | 12/28/16 | | |
| | | | | 7/31/19 | | | | | | Time | | | | | | 95,833 | | | | | | 104,167 | | | | | | 14.50 | | | | | | 7/31/29 | | |
| | | | | 7/31/19 | | | | | | Hybrid | | | | | | — | | | | | | 100,000(2) | | | | | | 14.50 | | | | | | 7/31/29 | | |
Total for Mr. Elam | | | | | | | | | | | | | | | | | 218,883 | | | | | | 212,917 | | | | | | | | | | | | | | |
Sankaram Mantripragada: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 3/26/14 | | | | | | Time | | | | | | 10,000 | | | | | | — | | | | | $ | 156.00 | | | | | | 3/26/21 | | |
| | | 2/23/15 | | | | | | Time | | | | | | 13,900 | | | | | | — | | | | | | 103.00 | | | | | | 2/23/25 | | | ||
| | | 5/12/17 | | | | | | Time | | | | | | 15,417 | | | | | | 4,583 | | | | | | 60.00 | | | | | | 5/12/27 | | | ||
| | | 6/30/17 | | | | | | Time | | | | | | 15,000 | | | | | | 5,000 | | | | | | 60.00 | | | | | | 6/30/27 | | | ||
| | | 7/31/19 | | | | | | Time | | | | | | 22,521 | | | | | | 24,479 | | | | | | 14.50 | | | | | | 7/31/29 | | | ||
| | | | | 7/31/19 | | | | | | Hybrid | | | | | | — | | | | | | 23,000(2) | | | | | | 14.50 | | | | | | 7/31/29 | | |
Total for Dr. Mantripragada | | | | | | | | | | | | | | | | | 76,838 | | | | | | 57,062 | | | | | | | | | | | | | | |
Keith Vendola: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 7/2/18 | | | | | | Time | | | | | | 9,583 | | | | | | 10,417 | | | | | $ | 26.00 | | | | | | 7/2/28 | | |
| | | 7/31/19 | | | | | | Time | | | | | | 19,167 | | | | | | 20,833 | | | | | | 14.50 | | | | | | 7/31/29 | | | ||
| | | | | 7/31/19 | | | | | | Hybrid | | | | | | — | | | | | | 20,000(2) | | | | | | 14.50 | | | | | | 7/31/29 | | |
Total for Mr. Vendola | | | | | | | | | | | | | | | | | 28,750 | | | | | | 51,250 | | | | | | | | | | | | | | |
Name | | | Grant Date | | | Number of Securities Underlying Unexercised Options | | | Option Exercise Price | | | Option Expiration Date | | ||||||||||||
| Exercisable | | | Unexercisable | | ||||||||||||||||||||
Nevan Charles Elam | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 7/31/19 | | | | | 195,833 | | | | | | 4,167(1) | | | | | $ | 14.50 | | | | 7/31/29 | |
| | | 6/14/21 | | | | | 125,000 | | | | | | 250,000(2) | | | | | | 12.28 | | | | 6/14/31 | |
| | | 6/23/22 | | | | | — | | | | | | 2,600,000(4) | | | | | | 3.40 | | | | 6/23/32 | |
Total for Mr. Elam | | | | | | | | 320,833 | | | | | | 2,854,167 | | | | | | | | | | | |
Brian Roberts, M.D. | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 7/31/19 | | | | | 39,166 | | | | | | 834(1) | | | | | $ | 14.50 | | | | 7/31/29 | |
| | | 6/14/21 | | | | | 37,500 | | | | | | 37,500(3) | | | | | | 12.28 | | | | 6/14/31 | |
| | | 6/23/22 | | | | | — | | | | | | 700,000(4) | | | | | | 3.40 | | | | 6/23/32 | |
Total for Dr. Roberts | | | | | | | | 76,666 | | | | | | 738,334 | | | | | | | | | | | |